Zuzana Tothova, MD, PhD
Photo: Zuzana Tothova

Interests/specialties:

Resources:

Elected 2026

Email: Zuzana_Tothova@DFCI.harvard.edu

Phone: 617-632-6848

Dr. Tothova is an Assistant Professor of Medicine at Harvard Medical School (HMS), the Edward P. Evans Investigator in the Department of Medical Oncology at the Dana-Farber Cancer Institute (DFCI), and Associate Member of the Broad Institute.  She received her B.A. in Biology and Chemistry from Williams College, a doctorate in Genetics from Harvard University in Dr. Gary Gilliland’s laboratory, and an M.D. from HMS/MIT in the Health Sciences and Technology program. She completed residency training in internal medicine at the Brigham and Women's Hospital and fellowship training in adult hematology and oncology at the DFCI and MGH Cancer Center. Dr. Tothova carried out her postdoctoral work in Dr. Benjamin Ebert’s laboratory at the Broad Institute. She established her independent laboratory at DFCI in 2018, where her research program focuses on cancer epigenetics and basic mechanistic and translational investigation of chromatin regulation during blood cancer development, with the ultimate goal of intercepting progression from clonal hematopoiesis to MDS and AML development. Dr. Tothova’s mechanistic investigations of the biology of cohesin-mutant MDS and AML have led to the development of a recently accrued Phase 1 clinical trial. Most recently, her lab has uncovered mechanisms by which STAG2 loss of function mutations activate innate immune signaling by driving R-loop formation and retroelement reactivation, with significant therapeutic implications. In addition to running an NIH/R01/P01-funded laboratory, Dr. Tothova also cares for patients on the inpatient leukemia service. Her work has been recognized by the Paragon award for research excellence from the Doris Duke Charitable Foundation(DDCF), the Career Award for Medical Scientists from the Burroughs Wellcome Fund and the Forbeck Foundation.  Dr. Tothova is also a recipient of multiple foundation grants from the American Society of Hematology, Leukemia and Lymphoma Society, DDCF, Edward P. Evans Foundation, Gabrielle’s Angel Foundation, and the RUNX1 Foundation/Alex's Lemonade Stand.